Recce Pharmaceuticals
Level 34, 50 Bridge Street
AMP Centre
Sydney
New South Wales
2000
Australia
Tel: 61-2-8216-0768
Website: http://www.recce.com.au/
Email: peter.williams@recce.com.au
About Recce Pharmaceuticals
Recce Ltd is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.
YEAR FOUNDED:
2007
LEADERSHIP:
Founder: Graham JH Melrose
CFO: Peter Williams
CLINICAL TRIAL:
69 articles with Recce Pharmaceuticals
-
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong, Strengthening Global IP Portfolio
2/3/2023
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced that it has been issued a trademark for RECCE® by the Trade Marks Registry Intellectual Property Department in Hong Kong.
-
Recce Pharmaceuticals Receives A$6.21 Million from Research and Development (R&D) Rebate Payments
1/27/2023
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce a total research and development (R&D) cash receipt of A$6,219,241.
-
Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
1/11/2023
Recce Pharmaceuticals Ltd is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection . ”
-
Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute
12/19/2022
Recce Pharmaceuticals Ltd announced the commencement of an Anti-Infective Research Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute.
-
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
10/18/2022
Recce Pharmaceuticals Ltd is pleased to provide an update from its preclinical studies evaluating RECCE® 327 (R327) against the SARS-CoV-2 virus.
-
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs
10/3/2022
Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.
-
Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
9/7/2022
Recce Pharmaceuticals Ltd is pleased to announce the appointment of Alistair McKeough to its Board of Directors.
-
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
-
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
7/12/2022
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to announce the appointment of Philip Sutton, Ph.D., as Vice President of Translational Sciences.
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
4/12/2022
Recce Pharmaceuticals Limited is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
3/30/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort four at 1,000mg (twenty-fold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among 10 healthy male subjects.
-
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
3/29/2022
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it has received a Research and Development Tax Incentive rebate of A$3,084,955.19 from the Australian Tax Office for the year ending June 30, 2021.
-
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
3/8/2022
Recce Pharmaceuticals Ltd is pleased to report an Independent Safety Committee data review of 10 healthy human subjects intravenously dosed in the Phase I intravenous clinical trial of RECCE® 327, demonstrating a good safety and tolerability profile – unanimously recommending cohort four to commence.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
2/8/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among seven healthy male subjects.